CD5 and cancer: Candidate biomarkers such as IL-7, TWEAK, 4E-BP, CXCL5, and CD5 are all actively involved in cancer initiation and progression in previous reports (18–22), and the KEGG analysis also indicated cancer pathway enrichment.